|
|
Profile
|
Delegates :
Takuro WAKABAYASHI |
|
Incorporated :
February 17 , 2005 |
Paid in Capital :
99 Million yen |
Employees :
7 人 |
Address :
1-23-3-5F, Miyamachi, Fuchu-shi TOKYO
〒183-0023
|
TEL/FAX :
+81-42-306-5078 / +81-42-306-5078 |
URL：
http://www.tms-japan.co.jp/en/index.html |
Attachment :
|
Mission/Background :
The mission of TMS is to enhance human wellness through new medical discoveries.
We are collaborating with Tokyo University of Agriculture and Technology, and develope a unique drug candidate from microbial library.
Ultimately, our goal is to help people suffering from a variety of diseases to recover their normal health and to improve their quality of life.
|
|
Technology & Business
|
We are developing small molecule drug candidates obtained from rich natural compound library at Tokyo University of Agriculture and Technology.
TMS-007 is an excellent stroke agent candidate with dual function, thrombolysis and cerebroprotection.
The P2 clinical trial of TMS-007 is ongoing.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
TMS-007
|
Phase2
|
TMS-007 is a novel stroke therapeutic drug candidate with dual mode of action, thrommbolysis and cerebroprotection.
|
Successful completion of phase 2 clinical trial.
|
TMS-00X
|
Discovery
|
TMS-00X is a novel small molecule with excellent anti-inflammation function.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
The phase I clinical trial of TMS-007 was completed successfully.
TMS-00X demonstrated excellent anti-inflammation efficacy with multiple animal models.
|
|
Alliance strategy
|
We are seeking development partners both for TMS-007 and TMS-00X.
|
|
|